Control of NF-kB activity in human melanoma by bromodomain and extra-terminal protein inhibitor I-BET151

The Epigenetic Regulator I-BET151 Induces BIM-Dependent Apoptosis and Cell Cycle Arrest of Human Melanoma Cells

(2014) Stuart J. Gallagher et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

BRD4 Sustains Melanoma Proliferation and Represents a New Target for Epigenetic Therapy

(2013) M. F. Segura et al.   CANCER RESEARCH

BET Protein Function Is Required for Inflammation: Brd2 Genetic Disruption and BET Inhibitor JQ1 Impair Mouse Macrophage Inflammatory Responses

(2013) A. C. Belkina et al.   JOURNAL OF IMMUNOLOGY

Brd4 maintains constitutively active NF-κB in cancer cells by binding to acetylated RelA

(2013) Z Zou et al.   ONCOGENE

The IKK Inhibitor Bay 11-7082 Induces Cell Death Independent from Inhibition of Activation of NFκB Transcription Factors

(2013) Hilka Rauert-Wunderlich et al.   PLoS One

Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas

(2012) Piro Lito et al.   CANCER CELL

Ikk4a/Arf Inactivation with Activation of the NF- B/IL-6 Pathway Is Sufficient to Drive the Development and Growth of Angiosarcoma

(2012) J. Yang et al.   CANCER RESEARCH

The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition

(2012) X. Jiang et al.   CLINICAL CANCER RESEARCH

NF- B, the first quarter-century: remarkable progress and outstanding questions

(2012) M. S. Hayden et al.   GENES & DEVELOPMENT

NF-κB and chromatin: ten years on the path from basic mechanisms to candidate drugs

(2012) Gioacchino Natoli   IMMUNOLOGICAL REVIEWS

Dimer-specific regulatory mechanisms within the NF-κB family of transcription factors

(2012) Stephen T. Smale   IMMUNOLOGICAL REVIEWS

Down-regulation of NF-κB Transcriptional Activity in HIV-associated Kidney Disease by BRD4 Inhibition

(2012) Guangtao Zhang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

NF-κB as potential target in the treatment of melanoma

(2012) Gabriele Madonna et al.   Journal of Translational Medicine

Evidence for upregulation of Bim and the splicing factor SRp55 in melanoma cells from patients treated with selective BRAF inhibitors

(2012) Fritz Lai et al.   MELANOMA RESEARCH

Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation

(2012) Jennifer Landsberg et al.   NATURE

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

(2012) Ravid Straussman et al.   NATURE

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

(2012) Timothy R. Wilson et al.   NATURE

BRD4 is an atypical kinase that phosphorylates Serine2 of the RNA Polymerase II carboxy-terminal domain

(2012) B. N. Devaiah et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma

(2012) Maria R. Girotti et al.   Cancer Discovery

The Unholy Trinity: Inflammation, Cytokines, and STAT3 Shape The Cancer Microenvironment

(2011) Ning Li et al.   CANCER CELL

Amino terminal hydrophobic import signals target the p14ARF tumor suppressor to the mitochondria

(2011) Mal Irvine et al.   CELL CYCLE

Role of nuclear factor-κB-mediated inflammatory pathways in cancer-related symptoms and their regulation by nutritional agents

(2011) Subash C Gupta et al.   EXPERIMENTAL BIOLOGY AND MEDICINE

Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia

(2011) Mark A. Dawson et al.   NATURE

NF-κB inducing kinase (NIK) modulates melanoma tumorigenesis by regulating expression of pro-survival factors through the β-catenin pathway

(2011) Y M Thu et al.   ONCOGENE

Inhibiting NF-κB activation by small molecules as a therapeutic strategy

(2010) Subash C. Gupta et al.   Biochimica et Biophysica Acta-Gene Regulatory Mechanisms

Molecular Mechanism of MART-1 + /A*0201 + Human Melanoma Resistance to Specific CTL-Killing Despite Functional Tumor–CTL Interaction

(2010) Ali R. Jazirehi et al.   CANCER RESEARCH

Requirement of the NF-κB Subunit p65/RelA for K-Ras–Induced Lung Tumorigenesis

(2010) Daniela S. Bassères et al.   CANCER RESEARCH

Suppression of inflammation by a synthetic histone mimic

(2010) Edwige Nicodeme et al.   NATURE

Selective inhibition of BET bromodomains

(2010) Panagis Filippakopoulos et al.   NATURE

NF-κB addiction and its role in cancer: ‘one size does not fit all’

(2010) M M Chaturvedi et al.   ONCOGENE

IKK  protein is a target of BAG3 regulatory activity in human tumor growth

(2010) M. Ammirante et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

QuickGO: a web-based tool for Gene Ontology searching

(2009) D. Binns et al.   BIOINFORMATICS

IKK/NF-κB and STAT3 pathways: central signalling hubs in inflammation-mediated tumour promotion and metastasis

(2009) Julia Bollrath et al.   EMBO REPORTS

CXCL8 and its cognate receptors in melanoma progression and metastasis

(2009) Seema Singh et al.   Future Oncology

The good and the bad of chemokines/chemokine receptors in melanoma

(2009) Ann Richmond et al.   Pigment Cell & Melanoma Research

The Lymphotoxin-β Receptor Is an Upstream Activator of NF-κB-mediated Transcription in Melanoma Cells

(2008) Punita Dhawan et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Brd4 Coactivates Transcriptional Activation of NF- B via Specific Binding to Acetylated RelA

(2008) B. Huang et al.   MOLECULAR AND CELLULAR BIOLOGY